JP2013518032A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518032A5
JP2013518032A5 JP2012533416A JP2012533416A JP2013518032A5 JP 2013518032 A5 JP2013518032 A5 JP 2013518032A5 JP 2012533416 A JP2012533416 A JP 2012533416A JP 2012533416 A JP2012533416 A JP 2012533416A JP 2013518032 A5 JP2013518032 A5 JP 2013518032A5
Authority
JP
Japan
Prior art keywords
substituent
hydrocarbon group
formula
anticancer agent
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012533416A
Other languages
English (en)
Japanese (ja)
Other versions
JP6131046B2 (ja
JP2013518032A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012533416A priority Critical patent/JP6131046B2/ja
Priority claimed from JP2012533416A external-priority patent/JP6131046B2/ja
Publication of JP2013518032A publication Critical patent/JP2013518032A/ja
Publication of JP2013518032A5 publication Critical patent/JP2013518032A5/ja
Application granted granted Critical
Publication of JP6131046B2 publication Critical patent/JP6131046B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012533416A 2010-01-27 2011-01-26 抗癌剤により誘発される末梢神経障害を抑制する化合物 Active JP6131046B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012533416A JP6131046B2 (ja) 2010-01-27 2011-01-26 抗癌剤により誘発される末梢神経障害を抑制する化合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010015935 2010-01-27
JP2010015935 2010-01-27
JP2012533416A JP6131046B2 (ja) 2010-01-27 2011-01-26 抗癌剤により誘発される末梢神経障害を抑制する化合物
PCT/JP2011/052077 WO2011093512A1 (en) 2010-01-27 2011-01-26 Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016056186A Division JP2016175903A (ja) 2010-01-27 2016-03-18 抗癌剤により誘発される末梢神経障害を抑制する化合物

Publications (3)

Publication Number Publication Date
JP2013518032A JP2013518032A (ja) 2013-05-20
JP2013518032A5 true JP2013518032A5 (enExample) 2014-02-13
JP6131046B2 JP6131046B2 (ja) 2017-05-17

Family

ID=43770309

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012533416A Active JP6131046B2 (ja) 2010-01-27 2011-01-26 抗癌剤により誘発される末梢神経障害を抑制する化合物
JP2016056186A Pending JP2016175903A (ja) 2010-01-27 2016-03-18 抗癌剤により誘発される末梢神経障害を抑制する化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016056186A Pending JP2016175903A (ja) 2010-01-27 2016-03-18 抗癌剤により誘発される末梢神経障害を抑制する化合物

Country Status (41)

Country Link
US (5) US20130046000A1 (enExample)
EP (1) EP2528598B1 (enExample)
JP (2) JP6131046B2 (enExample)
KR (1) KR20120118044A (enExample)
CN (2) CN104744321A (enExample)
AR (1) AR080024A1 (enExample)
AU (1) AU2011211294B2 (enExample)
BR (1) BR112012018434A2 (enExample)
CA (1) CA2788150C (enExample)
CL (1) CL2012002079A1 (enExample)
CO (1) CO6592110A2 (enExample)
CR (1) CR20120412A (enExample)
CY (1) CY1117268T1 (enExample)
DK (1) DK2528598T3 (enExample)
DO (1) DOP2012000209A (enExample)
EA (1) EA201290697A1 (enExample)
EC (1) ECSP12012126A (enExample)
ES (1) ES2560215T3 (enExample)
GE (1) GEP20166441B (enExample)
HR (1) HRP20160165T1 (enExample)
HU (1) HUE027310T2 (enExample)
IL (1) IL221066A (enExample)
MA (1) MA34014B1 (enExample)
ME (1) ME02364B (enExample)
MX (1) MX2012008514A (enExample)
MY (1) MY163936A (enExample)
NZ (1) NZ601635A (enExample)
PE (1) PE20121694A1 (enExample)
PH (1) PH12012501538A1 (enExample)
PL (1) PL2528598T3 (enExample)
PT (1) PT2528598E (enExample)
RS (1) RS54591B1 (enExample)
SG (2) SG10201503402XA (enExample)
SI (1) SI2528598T1 (enExample)
SM (1) SMT201600103B (enExample)
TN (1) TN2012000364A1 (enExample)
TW (1) TWI481401B (enExample)
UA (1) UA109540C2 (enExample)
UY (1) UY33203A (enExample)
WO (1) WO2011093512A1 (enExample)
ZA (1) ZA201205681B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150013143A (ko) * 2012-04-27 2015-02-04 니폰 조키 세야쿠 가부시키가이샤 트랜스-2-데센산 유도체 및 이것을 함유하는 의약
ES2763429T5 (es) * 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
US9611244B2 (en) 2015-05-08 2017-04-04 Takeda Pharmaceutical Company Limited Cyclic compounds
HRP20260689T1 (hr) 2015-06-17 2026-07-17 F. Hoffmann-La Roche Ag Postupci za liječenje lokalno uznapredovalog ili metastatskog raka dojke primjenom antagonista vezivanja osi pd-1 i taksana
RU2742337C2 (ru) * 2016-09-09 2021-02-04 Такеда Фармасьютикал Компани Лимитед Циклическое соединение
WO2019047812A1 (zh) * 2017-09-07 2019-03-14 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法
WO2021012138A1 (zh) 2019-07-22 2021-01-28 广州英赛特生物技术有限公司 二氨基胍衍生物及其饲用组合物在制备兽医用药物中的应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804374A (en) 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
EP0252146B1 (en) 1986-01-09 1994-05-25 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
WO1988005083A1 (en) 1986-12-24 1988-07-14 Whitehead Institute For Biomedical Research Method of inducible gene expression
WO1989007614A1 (en) 1988-02-12 1989-08-24 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
DE68910682T2 (de) 1988-03-01 1994-06-01 Whitehead Biomedical Inst Aktivierung der nf-kappa b-vorstufe.
AU5419690A (en) 1989-03-31 1990-11-05 Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5059712A (en) 1989-09-13 1991-10-22 Cornell Research Foundation, Inc. Isolating aminoarginine and use to block nitric oxide formation in body
US5158883A (en) 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
EP0557290A1 (en) 1990-08-23 1993-09-01 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
WO1992017168A1 (en) 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US6071876A (en) 1991-04-19 2000-06-06 Children's Medical Center Corporation Method of preventing NMDA receptor complex-mediated neuronal damage
ES2134804T3 (es) 1991-04-19 1999-10-16 Childrens Medical Center Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal.
KR19990022369A (ko) * 1995-06-07 1999-03-25 스테판 이반스-프레크 어뎁터 단백질/티로신 카이나제 상호작용을 방해하는 조성물과그 방법
US20020052019A1 (en) 1997-11-13 2002-05-02 Genentech Inc Human toll homologue
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
WO2001090151A2 (en) 2000-05-25 2001-11-29 Schering Corporation Human receptor proteins; related reagents and methods
AU1070399A (en) 1997-10-17 1999-05-10 Genentech Inc. Human toll homologues
ZA989147B (en) 1997-10-17 2000-04-07 Genentech Inc Human toll homologues.
AU1539499A (en) 1997-11-25 1999-06-15 Princeton University Method for preparing adenovirus vectors, vectors so prepared, and uses thereof
US20080275104A1 (en) 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20040072138A1 (en) 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
DK1063228T5 (da) 1998-03-09 2009-06-15 Takeda Pharmaceutical Cycloalkenderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf
WO2001010826A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. Substituted aromatic-ring compounds, process for producing the same, and use
SE9903930D0 (sv) * 1999-10-29 1999-10-29 Astra Pharma Inc Novel compounds and a novel process for their preparation
CN1416341B (zh) 2000-02-04 2010-05-05 武田药品工业株式会社 稳定的乳液组合物
CA2685447C (en) 2000-08-10 2013-05-28 Takeda Pharmaceutical Company Limited Pharmaceutical composition
KR100821546B1 (ko) 2000-10-18 2008-04-11 다케다 야쿠힌 고교 가부시키가이샤 광학 활성 술폰아미드의 제조 방법 및 그의 합성용 중간체
WO2002045470A1 (fr) 2000-11-30 2002-06-06 Tokuyama Corporation Substrat et procede de production correspondant
AU2002221099A1 (en) 2000-12-08 2002-06-18 Takeda Chemical Industries Ltd. Combination drugs
JP5137289B2 (ja) 2001-08-03 2013-02-06 武田薬品工業株式会社 安定な乳化組成物
EP1495756A4 (en) * 2002-04-08 2009-10-28 Takeda Pharmaceutical THERAPEUTIC AGENT FOR SEVERE SEPTIC STATE PREVENTION
US8710095B2 (en) 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20040259790A1 (en) 2003-01-30 2004-12-23 Bali Pulendran Methods for identifying and administering agents that bias the immune response via dendritic cells
EP1599726A4 (en) 2003-02-27 2009-07-22 3M Innovative Properties Co SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
EP1613956A2 (en) 2003-03-25 2006-01-11 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
EP1664342A4 (en) 2003-09-17 2007-12-26 3M Innovative Properties Co SELECTIVE MODULATION OF TLR GENE EXPRESSION
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
MY147790A (en) 2005-04-28 2013-01-31 Takeda Pharmaceutical Stable emulsion composition
JP5040650B2 (ja) 2005-06-03 2012-10-03 小野薬品工業株式会社 神経再生および/または保護剤
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
WO2007091790A1 (en) 2006-02-07 2007-08-16 Korea Institute Of Radiological & Medical Sciences A composition for treating damage of central or peripheral nerve system
ATE524732T1 (de) 2006-02-23 2011-09-15 Univ Yale Wirkstoffresistenz gegen pflanzenalkaloide basieren auf dem myd88-status in einer zelle und verfahren zum hemmen der signalgebung durch den tlr-4:myd88-signalweg
US7943588B2 (en) 2006-03-28 2011-05-17 Trustees Of Dartmouth College Method for preventing or treating neuropathic pain
EP1997902B1 (en) 2006-03-30 2013-09-18 Hiroshima University Screening method
JPWO2007123186A1 (ja) 2006-04-20 2009-09-03 武田薬品工業株式会社 医薬
JPWO2007132825A1 (ja) 2006-05-15 2009-09-24 武田薬品工業株式会社 医薬
US20090209585A1 (en) 2006-07-07 2009-08-20 Takashi Ichikawa Cycloalkene derivatives, process for production of the derivatives, and use of the same
EP1882687A1 (en) * 2006-07-27 2008-01-30 Amorepacific Corporation Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
WO2008112887A1 (en) 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US8399421B2 (en) 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
WO2009059050A2 (en) 2007-10-30 2009-05-07 The Regents Of The University Of Colorado Tlr modulators and methods for using the same
EP2262498A2 (en) 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
JP5238381B2 (ja) 2008-07-07 2013-07-17 スタンレー電気株式会社 照明用車両用灯具
EP2480536B1 (en) 2009-09-23 2014-08-13 The Regents of the University of Colorado, A Body Corporate Toll-like receptor modulators and uses thereof

Similar Documents

Publication Publication Date Title
JP2016503797A5 (enExample)
JP2013533253A5 (enExample)
JP2013537203A5 (enExample)
IN2014DN07283A (enExample)
JP2015524457A5 (enExample)
JP2019513770A5 (enExample)
JP2014524441A5 (enExample)
JP2010511721A5 (enExample)
CA2569850A1 (en) 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2,3-d] pyrimidine derivatives and related compounds for the treatment of cancer
JP2017511321A5 (enExample)
JP2011504903A5 (enExample)
JP2009514881A5 (enExample)
JP2011037841A5 (enExample)
JP2014500295A5 (enExample)
JP2013505946A5 (enExample)
JP2015501833A5 (enExample)
JP2013508288A5 (enExample)
RU2012155118A (ru) Способы лечения биполярного расстройства
JP2015504081A5 (enExample)
JP2014511366A5 (enExample)
RU2012109554A (ru) Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией
JP2007500734A5 (enExample)
JP2013063968A5 (enExample)
JP2010500962A5 (enExample)
JP2017510660A5 (enExample)